India's Leading DGFT Consultants

Amendments to SION A-222 for Export of Erythromycin Stearate Tablets

Amendments to SION A-222 for Export of Erythromycin Stearate Tablets

The Director General of Foreign Trade (DGFT) has recently made amendments to the Standard Input Output Norms (SION) A-222 concerning the export of Erythromycin Stearate Tablets, under the powers conferred by the Foreign Trade Policy-2023.

This amendment is part of the ongoing updates to streamline export procedures and ensure efficiency. Manufacturers and exporters involved in the production and export of Erythromycin Stearate Tablets should familiarize themselves with these changes to ensure compliance.

 

Export Product

Quantity

Sl. No.

Import Items

Quantity

Erythromycin Stearate

tablets-250 mg. (each tablet contains

erythromycin stearate

equivalent to 250 mg. of

Erythromycin.

 

1 Number Tablet

1

Erythromycin Stearate

 

334 Mg

Note: For other variants of export items, norms may be worked out on a pro-rata basis.

Effect of the Public Notice: Standard Input Output Norm appearing under A-222 is amended as above with immediate effect.

FeATURED ARTICLES

Related Posts